Market Closed –
Euronext Paris
11:55:00 2025-12-22 am EST
Pre-market
02:00:58 am
81.58 EUR
-0.97%
82.40
+1.01%
Published on 12/23/2025
at 01:41 am EST
MT Newswires
]]]]>]]>
© MT Newswires –
2025
01:41am
Sanofi, Regeneron’s Dupixent Wins Expanded Japanese Approval for Bronchial Asthma
MT
01:05am
Sanofi and Regeneron’s Dupixent approved in Japan for children with bronchial asthma
RE
Dec. 22
Berenberg Cuts Sanofi Price Target, Tweaks Estimates After Multiple Sclerosis Drug Updates
MT
Dec. 22
Sanofi Reaches Agreement with Trump Administration
Dec. 22
French and Benelux stocks-Factors to watch
RE
Dec. 21
Sanofi Agrees to Lower US Prices in Exchange for Tariff-free Period
MT
Dec. 19
Trump, pharmaceutical companies strike deal to cut drug prices
RE
Dec. 19
Sector Update: Health Care Stocks Rise Late Afternoon
MT
Dec. 19
Sector Update: Health Care
MT
Dec. 19
Sanofi Reports Deal with US Government to Lower Medicine Costs
MT
Dec. 19
Trump Reportedly Strikes Drug Price Deals With Nine Pharma Companies
MT
Dec. 19
Trump Reportedly Strikes Drug Price Deals With 9 Pharma Companies
MT
Dec. 19
Sanofi reaches agreement with US government to lower medicine costs while strengthening innovation
RE
Dec. 19
Sanofi, Trump Administration Reach Deal to Lower Medicine Costs
MT
Dec. 19
Sanofi Reaches Agreement with the US Government to Lower Medicine Costs While Strengthening Innovation
CI
Dec. 19
At least seven drug companies are set to announce price cuts with Trump at White House on Friday, including GlaxoSmithKline, Merck and Sanofi – Wapo
RE
Dec. 19
Trump, nine pharmaceutical companies strike deal to cut prices
RE
Dec. 19
SANOFI : Berenberg keeps its Buy rating
ZD
Dec. 17
AbbVie, several other pharma companies near MFN deal with Trump, sources say
RE
Dec. 17
Cytokinetics’ Hypertrophic Cardiomyopathy Treatment Approved in China
MT
Dec. 17
Cytokinetics announces NMPA approval of Myqorzo® in China
RE
Dec. 17
Sanofi Says Efdoralprin Alfa Gets Orphan Drug Designation in EU
MT
Dec. 17
DBV Technologies laughs, Euroapi cries
Dec. 17
Orphan drug designation in the DAAT for Sanofi
Dec. 17
Euroapi lowers its revenue forecast for 2025
DurationAuto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax.
PeriodDayWeek
SAN: Dynamic Chart
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
– pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);
– human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2024, the group had 52 production sites worldwide.
In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.
Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).
More about the company
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
More RatingsSell
Buy
Average target price
104.87EUR
Spread / Average Target
+28.54%
Consensus
OUR EXPERTS ARE HERE FOR YOU
Monday – Friday 9am-12pm / 2pm-6pm GMT + 1
Stock quotes are provided by Factset, Morningstar and S&P Capital IQ
Select your edition
All financial news and data tailored to specific country editions
AloJapan.com